Technical Analysis for GRAY - Graybug Vision, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Historical GRAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 2.00% | |
| Bearish Engulfing | Bearish | -6.03% | |
| Pocket Pivot | Bullish Swing Setup | -9.26% | |
| Doji - Bearish? | Reversal | -9.26% | |
| Hot IPO Pullback | Bullish Swing Setup | -6.92% | |
| Outside Day | Range Expansion | -6.92% | |
| Hot IPO Pullback | Bullish Swing Setup | -3.77% | |
| Up 3 Days in a Row | Strength | -8.47% | |
| Up 4 Days in a Row | Strength | -8.47% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Medicine Clinical Medicine Diseases Ophthalmology Macular Degeneration Wet Age Related Macular Degeneration Blindness Diabetic Retinopathy Macular Edema Diabetic Macular Edema Retinopathy Macula Of Retina Intravitreal Administration
Medicine Clinical Medicine Diseases Ophthalmology Macular Degeneration Wet Age Related Macular Degeneration Blindness Diabetic Retinopathy Macular Edema Diabetic Macular Edema Retinopathy Macula Of Retina Intravitreal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.69 |
| 52 Week Low | 12.5 |
| Average Volume | 136,305 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 14.72 |
| 10-Day Moving Average | 15.47 |
| Average True Range | 1.40 |
| ADX | 0.0 |
| +DI | 15.04 |
| -DI | 19.30 |
| Chandelier Exit (Long, 3 ATRs ) | 16.49 |
| Chandelier Exit (Short, 3 ATRs ) | 16.70 |
| Upper Bollinger Band | 17.00 |
| Lower Bollinger Band | 12.44 |
| Percent B (%b) | 0.52 |
| BandWidth | 30.97 |
| MACD Line | 0.39 |
| MACD Signal Line | 0.37 |
| MACD Histogram | 0.0239 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.38 | ||||
| Resistance 3 (R3) | 16.35 | 15.80 | 16.11 | ||
| Resistance 2 (R2) | 15.80 | 15.40 | 15.81 | 16.02 | |
| Resistance 1 (R1) | 15.30 | 15.15 | 15.55 | 15.33 | 15.94 |
| Pivot Point | 14.75 | 14.75 | 14.88 | 14.76 | 14.75 |
| Support 1 (S1) | 14.25 | 14.35 | 14.50 | 14.28 | 13.66 |
| Support 2 (S2) | 13.70 | 14.10 | 13.71 | 13.58 | |
| Support 3 (S3) | 13.20 | 13.70 | 13.49 | ||
| Support 4 (S4) | 13.23 |
